知镜 Cognispect · 医学文献与研究工作台

Urinary Volatile Organic Compounds as Pharmacodynamic Biomarkers in Sodium-glucose Cotransporter 2 Inhibitor-treated Diabetic Kidney Disease.

Mathew GG, Ramanathan G.
The Nigerian postgraduate medical journal · 2026-11-02 · PMID 42975214

文献摘要

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors confer renoprotection in diabetic kidney disease (DKD) through haemodynamic, anti-inflammatory and metabolic mechanisms, including hepatic ketogenesis induction. A recent investigation by Hara et al . demonstrated measurable elevations in urinary volatile organic compounds (VOCs), specifically acetone and 2-pentanone, in SGLT2 inhibitor-treated DKD patients using gas chromatography-mass spectrometry, providing direct metabolomic evidence of pharmacodynamic ketogenic interaction. This review contextualises these findings within the mechanistic framework of SGLT2 inhibitor-mediated renoprotection, particularly ketone body-induced suppression of mammalian target of rapamycin complex 1 in proximal tubular cells. This manuscript proposes three clinically actionable roles for urinary VOC monitoring: as a pharmacodynamic biomarker of drug engagement, a longitudinal marker of renoprotective responsiveness and a non-invasive early warning signal for euglycemic diabetic ketoacidosis. A pragmatic four-step algorithmic framework is presented to guide clinicians in integrating urinary VOC profiling with established DKD monitoring parameters. The key limitations including analytical confounders, acetoacetate instability and the need for point-of-care technology development are discussed in this minireview. Urinary VOC metabolomics represents a promising frontier in precision nephrology and individualised SGLT2 inhibitor-mediated DKD management.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。